Business Context and Reporting Period
Company: InfuSystem Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 2, 2016
Subject: Update regarding a policy change by the Centers for Medicare and Medicaid Services (CMS) known as "SE1609," issued on April 25, 2016. The policy clarifies that external infusion pumps and supplies provided to Medicare patients incident to a physician's service are no longer separately billable as Durable Medical Equipment (DME).
Key Financial Metrics and Exposure
- Medicare Revenue Exposure: Medicare accounted for 20% of total revenues for the three months ended March 31, 2016, and 19% for the fiscal year ended December 31, 2015.
- Accounts Receivable Exposure: Medicare represented 15% of consolidated accounts receivable as of March 31, 2016, and 20% as of December 31, 2015.
- Estimated Financial Impact: The transition to a temporary alternative billing arrangement is estimated to result in a net reduction to operating income of approximately $1 million annually.
- Commercial Revenue: The majority of the Company's revenues come from private commercial carriers, which the Company expects will not be directly materially impacted by SE1609.
Material Changes and Operational Shifts
The filing details a significant shift in billing procedures for Medicare patients:
- Previous Practice: The Company historically submitted billings directly to DME Medical Administrative Contractors (MACs) for infusion pumps and related services.
- New Requirement: Under SE1609, the Company can no longer bill DME MACs for these services. Instead, billings must be submitted to physicians or hospitals, who then seek reimbursement from Medicare. Consequently, physicians or hospitals become the primary obligors for payment rather than Medicare.
- Interim Actions: Pending further CMS guidance, the Company is holding billings for treatments post-May 10, 2016, and has instituted a temporary alternative billing arrangement with oncology clinic customers to preserve relationships and ensure a single source for home infusion treatment.
Outlook, Risks, and Management Commentary
- Uncertainty: The Company's interpretation of SE1609 is subject to change based on future CMS guidance. There are no assurances that the policy will not further impact future revenues or net income.
- Advocacy: Management intends to continue advocating for the safety, efficiency, and continuity of care for Medicare patients.
- Forward-Looking Statements: Statements regarding the anticipated impact of SE1609 and the alternative billing arrangement are forward-looking and subject to risks and uncertainties that may cause actual results to differ materially.
- Scope: The policy applies only to Medicare patients; private commercial carrier billing processes remain unchanged.
Key Facts for Investor Verification
- Verify the actual collection rates from physicians and hospitals under the new billing arrangement compared to direct Medicare billing.
- Monitor for further CMS guidance or interpretations that could alter the Company's current understanding of SE1609.
- Assess whether the estimated $1 million annual reduction in operating income is accurate or if the impact could be more severe due to held billings.
- Review the status of the $15 million (approx. 15% of AR) in Medicare-related accounts receivable as of March 31, 2016, to determine collection risk.